

Francesco Ciccia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6870308/publications.pdf>

Version: 2024-02-01

156
papers

6,845
citations

76031

42
h-index

87275

74
g-index

156
all docs

156
docs citations

156
times ranked

7675
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-life efficacy of guselkumab in patients with early psoriatic arthritis. <i>Rheumatology</i> , 2022, 61, 1217-1221.	0.9	15
2	Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2022, 21, 102925.	2.5	32
3	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , 2022, 41, 641-647.	1.0	6
4	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. <i>Rheumatology</i> , 2022, 61, 4124-4129.	0.9	16
5	Therapeutic Targets for Ankylosing Spondylitis – Recent Insights and Future Prospects. <i>Open Access Rheumatology: Research and Reviews</i> , 2022, Volume 14, 57-66.	0.8	7
6	Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2022, 9, e000681.	1.1	2
7	Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. <i>Scientific Reports</i> , 2022, 12, 7498.	1.6	7
8	Novel biomarker for pulmonary vascular disease in systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	2
9	Adult-onset Still's disease with elderly onset, results from a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	5
10	Satisfaction with Social Roles and Physical Function in Immune-mediated Inflammatory Diseases: A Cross-Sectional Study. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 177-186.	0.4	2
11	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF- β^2 and IL-6. <i>Pharmaceuticals</i> , 2022, 15, 622.	1.7	7
12	Epithelial HIF2 β expression induces intestinal barrier dysfunction and exacerbation of arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1119-1130.	0.5	4
13	Gut-derived CD8 ⁺ tissue-resident memory T cells are expanded in the peripheral blood and synovia of SpA patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e174-e174.	0.5	24
14	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	2.5	38
15	Novel immune cell phenotypes in spondyloarthritis pathogenesis. <i>Seminars in Immunopathology</i> , 2021, 43, 265-277.	2.8	23
16	Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. <i>Frontiers in Immunology</i> , 2021, 12, 637829.	2.2	140
17	The gut-joint axis in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 224-237.	3.5	160
18	Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study. <i>Lupus</i> , 2021, 30, 991-997.	0.8	15

#	ARTICLE	IF	CITATIONS
19	Inflammasome Activation in Ankylosing Spondylitis Is Associated With Gut Dysbiosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1189-1199.	2.9	32
20	Ankylosing spondylitis: an autoimmune or autoinflammatory disease?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 387-404.	3.5	130
21	Intestinal Microbial Metabolites in Ankylosing Spondylitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3354.	1.0	7
22	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 213.	1.6	25
23	Genetic and Environmental Determinants of T Helper 17 Pathogenicity in Spondyloarthropathies. <i>Frontiers in Genetics</i> , 2021, 12, 703242.	1.1	1
24	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021, 124, 102729.	3.0	23
25	Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1-11.	1.3	4
26	Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease. <i>Science Translational Medicine</i> , 2021, 13, eabg1210.	5.8	28
27	New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?. <i>Lancet Rheumatology</i> , The, 2021, 3, e874-e885.	2.2	8
28	Reply to: Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 224.	0.4	0
29	JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 668-675.	0.4	10
30	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 995-1002.	0.4	2
31	Incidence of COVID-19 in an Italian cohort of patients with systemic lupus erythematosus: an observational survey. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 128, 13.	0.4	1
32	The gut-entheses axis and the pathogenesis of Spondyloarthritis. <i>Seminars in Immunology</i> , 2021, 58, 101607.	2.7	7
33	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort. <i>Rheumatology International</i> , 2020, 40, 107-113.	1.5	20
34	Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation. <i>Arthritis and Rheumatology</i> , 2020, 72, 645-657.	2.9	51
35	Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 931-942.	1.3	5
36	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity" characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 151.	1.6	38

#	ARTICLE	IF	CITATIONS
37	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2020, 22, 127.	1.6	18
38	Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation. <i>Vaccines</i> , 2020, 8, 272.	2.1	14
39	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. <i>PLoS ONE</i> , 2020, 15, e0235326.	1.1	31
40	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020, 72, 1314-1324.	2.9	58
41	Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-217251.	0.5	25
42	Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. <i>Nature Communications</i> , 2020, 11, 1995.	5.8	253
43	What Does Human Leukocyte Antigen B27 Have to Do with Spondyloarthritis?. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 225-239.	0.8	6
44	An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 107-114.	0.4	6
45	Pathogenesis of primary Sjogren's syndrome beyond B lymphocytes. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 315-323.	0.4	4
46	Title is missing!. , 2020, 15, e0235326.		0
47	Title is missing!. , 2020, 15, e0235326.		0
48	Title is missing!. , 2020, 15, e0235326.		0
49	Title is missing!. , 2020, 15, e0235326.		0
50	Invariant NKT Cells and Rheumatic Disease: Focus on Primary Sjogren Syndrome. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5435.	1.8	16
51	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019, 21, 204.	1.6	40
52	ILC3 in Axial Spondyloarthritis: the Gut Angle. <i>Current Rheumatology Reports</i> , 2019, 21, 37.	2.1	26
53	Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. <i>Scientific Reports</i> , 2019, 9, 7144.	1.6	18
54	Pathogenesis of Ankylosing Spondylitis. , 2019, , 97-110.		0

#	ARTICLE	IF	CITATIONS
55	Gut dysbiosis in Spondyloarthritis: Cause or effect?. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101493.	1.4	14
56	Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine (United States), 2019, 98(10), 171-177.	0.84	10
57	Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. Arthritis Research and Therapy, 2019, 21, 275.	1.6	20
58	Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology, 2019, 58, 963-968.	0.9	42
59	The Craniovertebral Junction in Rheumatoid Arthritis: State of the Art. Acta Neurochirurgica Supplementum, 2019, 125, 79-86.	0.5	11
60	Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis. Clinical and Experimental Rheumatology, 2019, 37, 1096.	0.4	4
61	T2-mapping of the sacroiliac joints at 1.5 Tesla: a feasibility and reproducibility study. Skeletal Radiology, 2018, 47, 1691-1696.	1.2	18
62	Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. Journal of Rheumatology, 2018, 45, 864-872.	1.0	70
63	Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 1265-1275.	2.9	18
64	Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease. Journal of Rheumatology, 2018, 45, 630-637.	1.0	23
65	CD3 immunohistochemistry is helpful in the diagnosis of giant cell arteritis. Rheumatology, 2018, 57, 1377-1380.	0.9	8
66	Response to: 'Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries' by Graver et al. Annals of the Rheumatic Diseases, 2018, 77, e17-e17.	0.5	2
67	Increased expression of interleukin-22 in patients with giant cell arteritis. Rheumatology, 2018, 57, 64-72.	0.9	20
68	Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. Arthritis Research and Therapy, 2018, 20, 223.	1.6	29
69	Role of Subclinical Gut Inflammation in the Pathogenesis of Spondyloarthritis. Frontiers in Medicine, 2018, 5, 63.	1.2	27
70	Intestinal Involvement in Kawasaki Disease. Journal of Pediatrics, 2018, 202, 186-193.	0.9	55
71	Proinflammatory CX3CR1+CD59+Tumor Necrosis Factor-Like Molecule 1A+Interleukin-23+ Monocytes Are Expanded in Patients With Ankylosing Spondylitis and Modulate Innate Lymphoid Cell 3 Immune Functions. Arthritis and Rheumatology, 2018, 70, 2003-2013.	2.9	39
72	Î²-amyloid wall deposit of temporal artery in subjects with spontaneous intracerebral haemorrhage. Oncotarget, 2018, 9, 34699-34707.	0.8	3

#	ARTICLE	IF	CITATIONS
73	The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 210-214.	0.4	26
74	Cardiovascular Disease in Primary Sjögren's Syndrome. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 164-169.	0.4	8
75	Interstitial lung disease in systemic sclerosis: current and future treatment. <i>Rheumatology International</i> , 2017, 37, 853-863.	1.5	76
76	Ectopic expression of CXCL13, BAFF, APRIL and LT- α is associated with artery tertiary lymphoid organs in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 235-243.	0.5	67
77	Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1123-1132.	0.5	226
78	New insights into the pathogenesis of giant cell arteritis. <i>Autoimmunity Reviews</i> , 2017, 16, 675-683.	2.5	51
79	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1247-1260.	0.9	15
80	Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1796-1806.	2.9	61
81	Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e31-e31.	0.5	40
82	Brief Report: Functional Interaction of Endoplasmic Reticulum Aminopeptidase 2 and HLA-B*27 Activates the Unfolded Protein Response. <i>Arthritis and Rheumatology</i> , 2017, 69, 1009-1015.	2.9	14
83	Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1041-1047.	1.3	36
84	Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis. <i>Medicine (United States)</i> , 2017, 96, e7896.	0.4	42
85	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.) <i>TJ ETQq1 1 0.784314 rgBT /Overlock</i>	2.5	107
86	IL-17 polarization of MAIT cells is derived from the activation of two different pathways. <i>European Journal of Immunology</i> , 2017, 47, 2002-2003.	1.6	26
87	Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. <i>Autoimmunity Reviews</i> , 2017, 16, 16-21.	2.5	65
88	CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjögren's syndrome patients and correlates with focus score and disease activity. <i>Arthritis Research and Therapy</i> , 2017, 19, 178.	1.6	41
89	Gut inflammation in spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 863-876.	1.4	31
90	H-ferritin and CD68+/H-ferritin+ monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease. <i>Clinical and Experimental Immunology</i> , 2016, 186, 30-38.	1.1	40

#	ARTICLE	IF	CITATIONS
91	The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pathogenesis. <i>Clinical and Experimental Immunology</i> , 2016, 183, 397-404.	1.1	29
92	Subclinical gut inflammation in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 89-96.	2.0	61
93	Intestinal dysbiosis and innate immune responses in axial spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 352-358.	2.0	24
94	Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. <i>BMC Medicine</i> , 2016, 14, 194.	2.3	130
95	Endothelial progenitor cells: Are they displaying a function in autoimmune disorders?. <i>Mechanisms of Ageing and Development</i> , 2016, 159, 44-48.	2.2	13
96	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. <i>Clinical Rheumatology</i> , 2016, 35, 1683-1689.	1.0	83
97	Non-conventional forms of HLA-B27 are expressed in spondyloarthritis joints and gut tissue. <i>Journal of Autoimmunity</i> , 2016, 70, 12-21.	3.0	24
98	Autophagy in the pathogenesis of ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2016, 35, 1433-1436.	1.0	21
99	Tocilizumab therapy for unresponsive pulmonary arterial hypertension in a patient with Takayasu arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 251-252.	0.6	6
100	Interleukin-9 and T helper type 9 cells in rheumatic diseases. <i>Clinical and Experimental Immunology</i> , 2016, 185, 125-132.	1.1	44
101	The role of the gastrointestinal tract in the pathogenesis of rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 889-900.	1.4	23
102	Clinical efficacy of $\alpha 4$ integrin block with natalizumab in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2053-2054.	0.5	17
103	Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1922-1931.	2.9	80
104	Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. <i>Journal of Rheumatology</i> , 2016, 43, 1340-1349.	1.0	45
105	IL-1 β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 849-855.	1.3	46
106	Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 252-266.	1.0	32
107	Invariant NKT cells are expanded in peripheral blood but are undetectable in salivary glands of patients with primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 25-31.	0.4	3
108	Erratum to "Cells minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study" [Semin Arthritis Rheum 44 (2014) 314-324]. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, e23.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Use of Rituximab in the Management of Sjögren's Syndrome. Current Treatment Options in Rheumatology, 2015, 1, 277-291.	0.6	3
110	Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjögren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. Clinical and Experimental Immunology, 2015, 181, 219-229.	1.1	38
111	Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1 β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3 (NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clinical and Experimental Immunology, 2015, 182, 35-44.	1.1	100
112	Cell Immunity in Inflammatory Vasculitis. Current Immunology Reviews, 2015, 11, 3-11.	1.2	0
113	Disease-associated polymorphisms in ERAP1 do not alter endoplasmic reticulum stress in patients with ankylosing spondylitis. Genes and Immunity, 2015, 16, 35-42.	2.2	29
114	Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. Arthritis and Rheumatology, 2015, 67, 686-691.	2.9	340
115	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. Autoimmunity Reviews, 2015, 14, 429-437.	2.5	46
116	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. Cytotherapy, 2015, 17, 832-849.	0.3	19
117	Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatology, 2015, 54, 2264-2272.	0.9	83
118	Interleukin-36 axis is modulated in patients with primary Sjögren's syndrome. Clinical and Experimental Immunology, 2015, 181, 230-238.	1.1	95
119	Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2015, 74, 1739-1747.	0.5	236
120	Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. Rheumatology, 2015, 54, 1596-1604.	0.9	66
121	The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-10 producing Th17 lymphocytes in patients with early rheumatoid arthritis. Rheumatology International, 2015, 35, 171-175.	1.5	33
122	Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity. Rheumatology, 2014, 53, 1307-1312.	0.9	17
123	Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. Rheumatology, 2014, 53, 1313-1320.	0.9	41
124	Response to IL-23 expression and activation of autophagy in synovium and PBMCs of HLA-B27 positive patients with ankylosing spondylitis by Neerincx et al.. Annals of the Rheumatic Diseases, 2014, 73, e69-e69.	0.5	1
125	The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome. Expert Review of Clinical Immunology, 2014, 10, 533-541.	1.3	22
126	Macrophage phenotype in the subclinical gut inflammation of patients with ankylosing spondylitis. Rheumatology, 2014, 53, 104-113.	0.9	44

#	ARTICLE	IF	CITATIONS
127	Rituximab in primary Sjögren's syndrome: a ten-year journey. <i>Lupus</i> , 2014, 23, 1337-1349.	0.8	21
128	Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1566-1574.	0.5	145
129	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 314-324.	1.6	61
130	Exosomes as Intercellular Signaling Organelles Involved in Health and Disease: Basic Science and Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2013, 14, 5338-5366.	1.8	328
131	IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 258-264.	0.5	55
132	Jejunioileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 441-452.	1.3	18
133	IL-34 is overexpressed in the inflamed salivary glands of patients with Sjogren's syndrome and is associated with the local expansion of pro-inflammatory CD14 ^{bright} CD16 ⁺ monocytes. <i>Rheumatology</i> , 2013, 52, 1009-1017.	0.9	92
134	Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. <i>Arthritis Research and Therapy</i> , 2013, 15, R172.	1.6	143
135	Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 782-783.	0.5	29
136	Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 295-301.	0.5	143
137	Are Toll-Like Receptors and Decoy Receptors Involved in the Immunopathogenesis of Systemic Lupus Erythematosus and Lupus-Like Syndromes?. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-5.	3.3	12
138	Increased expression of interleukin-32 in the inflamed ileum of ankylosing spondylitis patients. <i>Rheumatology</i> , 2012, 51, 1966-1972.	0.9	24
139	Interleukin-22 and interleukin-22-producing NKp44 ⁺ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1869-1878.	6.7	111
140	One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. <i>Rheumatology International</i> , 2011, 31, 33-37.	1.5	67
141	Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2097-2104.	6.7	31
142	Successful intravenous immunoglobulin treatment for steroid-resistant eosinophilic enteritis in a patient with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 1018-20.	0.4	13
143	A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. <i>Rheumatology International</i> , 2010, 30, 1437-1440.	1.5	41
144	Expansion of intestinal CD4 ⁺ CD25 ^{high} Treg cells in patients with ankylosing spondylitis: A putative role for interleukin-10 in preventing intestinal Th17 response. <i>Arthritis and Rheumatism</i> , 2010, 62, 3625-3634.	6.7	53

#	ARTICLE	IF	CITATIONS
145	Over-expression of paneth cell-derived anti-microbial peptides in the gut of patients with ankylosing spondylitis and subclinical intestinal inflammation. <i>Rheumatology</i> , 2010, 49, 2076-2083.	0.9	43
146	Phenotype and functional changes of VÎ³9/VÎ²2 T lymphocytes in Behçet's disease and the effect of infliximab on VÎ³9/VÎ²2 T cell expansion, activation and cytotoxicity. <i>Arthritis Research and Therapy</i> , 2010, 12, R109.	1.6	28
147	Overexpression of interleukinâ€23, but not interleukinâ€17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 955-965.	6.7	215
148	Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intimaâ€media thickness in female patients with active rheumatoid arthritis. <i>Rheumatology International</i> , 2009, 30, 193-198.	1.5	33
149	IVIg in APS pregnancy. <i>Lupus</i> , 2004, 13, 731-735.	0.8	23
150	Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2003, 48, 728-731.	6.7	206
151	Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease. <i>Arthritis Research</i> , 2003, 5, R262.	2.0	35
152	Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 280-281.	0.5	62
153	Prevalence of headache in patients with Behcet's disease without overt neurological involvement. <i>Cephalalgia</i> , 2003, 23, 105-108.	1.8	26
154	Humoral and cell mediated immune response to cow's milk proteins in Behcet's disease. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 459-462.	0.5	18
155	Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 560-561.	0.5	60
156	Interleukin 9 neutralisation reduces collagen-induced arthritis severity in mouse models. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1